BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Year virus'. (Return)

Yahoo BusinessSep 20, 2020
Moderna Reveals Efficacy Criteria For Key Covid-19 Vaccine Trials
Moderna (MRNA) has taken the rare step of publishing the clinical protocols for its late-stage Covid-19 vaccine trials. The company also announced that it is planning to produce roughly 20M doses of its vaccine candidate, mRNA-1273, this year.According to the published protocol, Moderna is carrying out a Phase 3, randomized, stratified, observer-blind, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of mRNA-1273 against the SARS-CoV-2 vaccine in adults aged 18 and over.The study will target adults who have no known history of SARS-CoV-2 infection but whose locations or circumstances put them at risk of catching the virus.Its primary endpoint is to demonstrate the efficacy of mRNA-1273 to prevent the first occurrence of Covid-19 starting 14 days after the second dose.Here Covid-19 is defined as symptomatic disease based on the following criteria: at least two of fever (= 38ºC), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and a positive coronavirus test.It will also evaluate the safety and reactogenicity of 2 injections of mRNA-1273 given 28?days apart.Secondary endpoints include evaluating the efficacy of mRNA-1273 to prevent severe Covid-19, asymptomatic Covid-19, to evaluate vaccine efficacy (VE) to prevent death caused by the virus, and to evaluate the efficacy of
TRENDING TAGS
TrumpTikTok deal Court Supreme Oracle
TikTokTrump deal Oracle Walmart Ban
Covid-19Matt Hancock warns national lockdowns
StockBuy Market Dividend Cannabis Right
WeChatban judge Trump blocks app
coronavirusVaccine states see increase cases
BanTrump judge TikTok WeChat Deal
ChinaTikTok foreign ByteDance seeks billion
dealTikTok Trump Oracle App Ban
SupremeCourt Trump Ginsburg Ruth Bader

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC